No-deal Brexit could ‘irreparably’ harm NHS and delay drugs: BMA

Leaving the EU without a deal in place could “irreparably” harm the UK’s National Health Service (NHS) and lead to delays in new products being bought to market in the country, according to the British Medical Association (BMA).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Accord’s generic hopes dashed in cyanide antidote ruling

14 October 2026 Efforts to bring a generic cyanide poisoning treatment to market have suffered a setback after a US judge rejected challenges to three patents and criticised the drugmaker’s interpretation of the treatment’s chemical composition.

Pharma

Novo’s semaglutide protection weakens after European ruling

13 October 2026 Generic challengers have scored a win against the Danish company after an appeals board revoked a key patent covering the cardiovascular use of semaglutide. The decision strips away another layer of protection as generic manufacturers hunt down the semaglutide franchise.

Pharma

Novartis pursues Apotex over copies of $2bn skin cancer drug franchise

8 October 2026 Following ANDA litigation over Tafinlar earlier this year, the Swiss multinational has sued the generics maker over its proposed version of Mekinist, asserting patents that cover both the composition and treatment regimen.

More features

Haynes Boone expands in California with new office

Accord’s generic hopes dashed in cyanide antidote ruling

Novo’s semaglutide protection weakens after European ruling

UK to clamp down on non-compete clauses and long notice periods

Boston Scientific expands dispute with J&J unit over cardiac-access technology

Brazilian firm appoints patent strategist to lead department

AIPPI World Congress: ‘Diversity need not be an obstacle to unity’

Novartis pursues Apotex over copies of $2bn skin cancer drug franchise

No-deal Brexit could ‘irreparably’ harm NHS and delay drugs: BMA

More on this story

Editor's picks

Editor's picks

More features